16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
Completed · Phase 3 · Has a placebo group
Conditions studied: Spondylitis, Ankylosing
In brief
The purpose of this study was to generate 16-week efficacy data, as well as up to 3-year efficacy, safety and tolerability data in subjects with active AS despite current or previous NSAID, DMARD and/or anti-TNF therapy.
Key facts
- Study ID
- NCT02008916
- Run by
- Novartis Pharmaceuticals
- People needed
- 226
- Starts
- 2014-01-14
- Expected to finish
- 2017-12-11
- Last updated by the study team
- 2019-01-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Mesa, Arizona, United States
- Novartis Investigative Site — Peoria, Arizona, United States
- Novartis Investigative Site — Upland, California, United States
- Novartis Investigative Site — Palm Harbor, Florida, United States
- Novartis Investigative Site — Pembroke Pines, Florida, United States
- Novartis Investigative Site — Passaic, New Jersey, United States
- Novartis Investigative Site — Albany, New York, United States
- Novartis Investigative Site — Oklahoma City, Oklahoma, United States
- Novartis Investigative Site — Duncansville, Pennsylvania, United States
- Novartis Investigative Site — Charleston, South Carolina, United States
- Novartis Investigative Site — Jackson, Tennessee, United States
- Novartis Investigative Site — Austin, Texas, United States
- Novartis Investigative Site — Mesquite, Texas, United States
- Novartis Investigative Site — Aalst, Belgium
- Novartis Investigative Site — Brussels, Belgium
- Novartis Investigative Site — Uherské Hradiště, Czech Republic, Czechia
- Novartis Investigative Site — Prague, Czechia
- Novartis Investigative Site — Bad Doberan, Germany
- Novartis Investigative Site — Berlin, Germany
- Novartis Investigative Site — Berlin, Germany
- Novartis Investigative Site — Cottbus, Germany
- Novartis Investigative Site — Erlangen, Germany
- Novartis Investigative Site — Erlangen, Germany
- Novartis Investigative Site — Göttingen, Germany
- Novartis Investigative Site — Mobile, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.